1. Home
  2. News
  3. Imugene Ltd
  4. Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
More Imugene Ltd news
Imugene LtdASX: IMU

Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA

Nov 1, 2020 at 10:12 PM EST · Issued by Imugene Ltd

Filed with ASX · Nov 1, 2020 at 10:12 PM EST · 2 pages · English

On 6ix: 6ix.com/news/imugene-receives-fda-ind-approval-for-pd1-vaxx-trial-in-usa

Imugene Ltd on 6ix

Story so far

  • Imugene Receives PD1-VAXX Ethics Trial Approval in USASep 3, 2020
  • Imugene Receives Third PD1-VAXX Ethics Trial ApprovalAug 21, 2020
  • Imugene Receives Second PD1-VAXX Ethics Trial ApprovalJul 17, 2020

Earlier from Imugene

  • Imugene Immunotherapy Combination Patent Granted in USOct 1, 2020
  • Imugene Secures $5.7 million Option Underwriting AgreementSep 8, 2020
  • Imugene Receives PD1-VAXX Ethics Trial Approval in USASep 3, 2020
  • Appendix 4E & Annual Report to shareholdersAug 31, 2020
  • Imugene Receives Third PD1-VAXX Ethics Trial ApprovalAug 20, 2020

Later from Imugene

  • Imugene HER Vaxx shows positive Overall Survival in trialNov 22, 2020
  • Imugene First Patient Dosed in PD1-VAXX Clinical TrialNov 30, 2020
  • Imugene Receives $4.82 million R&D Tax IncentiveDec 10, 2020
  • Imugene Enrols First Cohort of PD1-Vaxx Clinical TrialDec 16, 2020
  • Imugene completes recruitment to HER-Vaxx Phase 2 trialimJan 6, 2021
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer